Afrezza是印度第一个可吸入的胰岛素, Cipla gains approval to distribute Afrezza, the first inhalable insulin, in India.

印度药物制造者Cipla已经得到印度监管者的批准, 向糖尿病患者分发第一种可吸入的胰岛素Afrezza。 Indian drug maker Cipla has been approved by Indian regulators to distribute Afrezza, the first inhalable insulin for diabetes patients. Afrezza由美国公司Mannkind开发, 提供无针治疗糖尿病的选择, 通过吸入改善血糖控制。 Developed by US company MannKind, Afrezza offers a needle-free option for managing diabetes, improving glycemic control through inhalation. 该产品经美国批准十多年,旨在为印度数百万糖尿病患者提供更方便的治疗。 The product, approved in the US for over a decade, aims to provide a more convenient treatment for millions of diabetes patients in India.